We are live on ! Find out more
IDXG

Interpace Biosciences, Inc. Common Stock
IDXG

Delisted

IDXG was delisted on the 24th of February, 2021.

19 hedge funds and large institutions have $2.98M invested in Interpace Biosciences, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% less funds holding

Funds holding: 2219 (-3)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

74% less capital invested

Capital invested by funds: $11.5M → $2.98M (-$8.48M)

Holders
19
Holders Change
-3
Holders Change %
-13.64%
% of All Funds
0.5%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
3
Reduced
5
Closed
5
Calls
Puts
Net Calls
Net Calls Change

IDXG Hedge Fund Activity: Q4 2015 in Review

19 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q4 2015, worth a combined $2.98M — down 74% from $11.5M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of IDXG and 2 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 3 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $14K. The largest seller was Shepherd Kaplan Krochuk, exiting entirely with an estimated $195K sold.

  • 19 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q4 2015, down from 22 in Q3 2015.
  • Funds reported $2.98M of Interpace Biosciences, Inc. Common Stock stock for Q4 2015, down 74% quarter-over-quarter.
  • 2 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q4 2015 and 5 closed out, a net change of -3 holders.
  • The largest Interpace Biosciences, Inc. Common Stock buyer in Q4 2015 was Two Sigma Securities, an estimated $14K added.
  • The largest Interpace Biosciences, Inc. Common Stock seller in Q4 2015 was Shepherd Kaplan Krochuk, an estimated $195K sold.

Based on aggregated 13F filings for Q4 2015.